•  
  •  
  •  
  •  

2025-11-29 03:26:52

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Veefin Wins Supply Chain Finance Mandate from Bank of the Philippine Islands for Philippines Deployment
  • Arvind SmartSpaces adds a new premium residential high-rise project in Ahmedabad with a top-line potential of ~Rs. 400 crore
  • MAHAGENCO and NTPC consortium's resolution plan for Sinnar Thermal Power Ltd approved by NCLT
  • Patel Engineering Ltd fixes Dec 4, 2025 as record date for 7:40 rights issue
  • Ramky Infrastructure Ltd wins award ET INFRA LEADERSHIP Awards 2025

Keywords Selected:  NATCOPharma

Research

  • Natco Pharma - Natco and Teva launch Revlimid in the US - ICICI Securities

Stock Report

  • NATCO Pharma Ltd receives 7 Observations from USFDA for API unit at Manali, Chennai
  • Adcock ingram completes delisting from JSE; NATCO Pharma acquires 35.75% stake
  • NATCO announces launch of its Everolimus tablets, 1 mg, (generic of Zortress®)
  • NATCO Pharma Limited - Legal update regarding Risdiplam
  • Legal update regarding Risdiplam - Commercial Appellate Division of the Hon'ble Delhi High Court Dismissed Appeal
  • NATCO Pharma Ltd updates on acquisition of Adcock Ingram
  • NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
  • NATCO Pharma Ltd announces conclusion of USFDA inspection at Pharma Division, Kothur
  • USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad
  • NATCO Pharma Ltd - Legal Update regarding Risdiplam
  • Mylan and Novo Nordisk reach settlement of US patent ligitation related to Ozempic
  • NATCO Pharma Canada Inc. announces US$ 8 million investment in eGenesis, Inc.
  • Natco Pharma Ltd announces submission of Abbreviated New Drug Application
  • NATCO Pharma Ltd updates on complaint by Fresenius
  • NATCO Pharma Ltd receives warning letter from USFDA for facility in Kothur, Telangana
  • NATCO Pharma Limited invests around US$ 2 million in Cellogen Therapeutics Private Limited
  • Natco Pharma Ltd and Breckenridge dismissed from antitrust lawsuit
  • Operations disrupted at NATCO Pharma's Manali, Chennai factory
  • Natco Pharma Ltd posts consolidated Q2FY24 PAT of Rs. 369 crores
  • NATCO Pharma announces successful completion of USFDA inspection
  • Natco Pharma Ltd receives 8 observations from USFDA for Pharma Division at Kothur
  • NATCO Pharma Ltd included as defendant in antitrust lawsuit in the US
  • Natco Pharma's consolidated PAT in Q1FY24 jumps to Rs. 420.3 crores
  • NATCO files generic Erdafitinib Tablets in USA

Latest Post

  • Veefin Wins Supply Chain Finance Mandate from Bank of the Philippine Islands for Philippines Deployment
  • Arvind SmartSpaces adds a new premium residential high-rise project in Ahmedabad with a top-line potential of ~Rs. 400 crore
  • MAHAGENCO and NTPC consortium's resolution plan for Sinnar Thermal Power Ltd approved by NCLT
  • Patel Engineering Ltd fixes Dec 4, 2025 as record date for 7:40 rights issue
  • Ramky Infrastructure Ltd wins award ET INFRA LEADERSHIP Awards 2025


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024